Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic and molecular remissions. However, approximately 15–20% fail to obtain optimal responses ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Massimino, Michele, Stella, Stefania, Tirrò, Elena, Romano, Chiara, Pennisi, Maria Stella, Puma, Adriana, Manzella, Livia, Zanghì, Antonino, Stagno, Fabio, Di Raimondo, Francesco, Vigneri, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817805/
https://www.ncbi.nlm.nih.gov/pubmed/29455672
http://dx.doi.org/10.1186/s12943-018-0805-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817805/
https://www.ncbi.nlm.nih.gov/pubmed/29455672
http://dx.doi.org/10.1186/s12943-018-0805-1

Ejemplares similares